Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
All of the addiction medicine specialists reported they had prescribed GLP-1RAs for weight loss, while 80 percent of gastroenterologists had done so, with other surveyed specialists ranging from 88 to 96 percent
Introduction Over a decade ago, the first injectable glucagon-like peptide-1 receptor agonist (GLP-1) for type 2 diabetes mellitus (T2DM) was approved by the Food and Drug Administration (FDA) for chronic weight management
Its ability to modulate the hepatocyte growth factor (HGF)/c-Met system provides a functional platform for exploring molecular events underlying cognitive processes
Also, the inclusion of the drugs in public drug formularies and expanded insurance coverage for chronic condition management escalates accessibility, especially for underserved populations, and is driving the demand and growth of the market
DOI: 10.3389/fneur.2022.844697 4
US$ 25.41
US$ 28.88
US$ 27.59
US$ 26.73
US$ 24.79
US$ 27.47
